Scott Tyldesley, MD, FRCPC, on Localized Prostate Cancer: External Beam vs Brachytherapy Boost RT

February 26, 2026 By The ASCO Post Staff

Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, reports on the 15-year survival analysis from the ASCENDE-RT trial, which randomly assigned patients to receive either prostate brachytherapy or the external-beam radiotherapy boost; both arms also received androgen-deprivation therapy. Fifteen-year overall survival and cumulative risk of death from prostate cancer were analyzed (Abstract 306). 

Related Content